Global Postoperative Pain Pipeline Market Research Report 2022: Comprehensive Insights about 55+ Companies and 55+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Postoperative Pain – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Postoperative Pain pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.

Postoperative Pain Emerging Drugs Chapters

This segment of the Postoperative Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postoperative Pain Emerging Drugs

VVZ-149: Vivozon

VVZ-149 is a new mechanism-based non-narcotic and non-NSAID analgesic demonstrating the robust (comparable to morphine) pain-suppressing efficacy in a panel of in vivo models (post-operative, formalin-induced or neuropathic pain model). The compound has also shown the anti-itching effect in the serotonin-induced itching model. These in vivo efficacies are attributed to the synergistic or additive dual antagonistic activity of VVZ-149 against GlyT2 and 5HT2A which are key receptors for the transmission of the pain signal in spinal dorsal horn area and/or peripheral sensory neurons.

Qutenza: Grunenthal

Qutenza (capsaicin) 8% topical system is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. It is currently in Phase III stage of development for the treatment of Post-surgical neuropathic pain.

CYT-1010: Cytogel Pharma

CYT-1010 is the first member of a new class of drugs, the endomorphins, to reach clinical development. It produces pain relief through a novel mechanism of action on the endomorphin (EM) receptor. CYT-1010, is entering Phase II clinical development, following a successful Phase I study in humans. This breakthrough pain medicine has shown reduced potential for addiction and significantly less risk of respiratory depression, relative to treatment with traditional pain medicines.

ACP-044: ACADIA Pharmaceuticals

ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic. The mechanism of action is thought to interrupt multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a by-product of tissue damage. A Phase II study was initiated evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery in March 2021.

CAM2048: Camurus

CAM2048 is a buprenorphine depot formulation for the treatment of postoperative pain providing rapid onset of action and therapeutic buprenorphine plasma levels over a couple of days. CAM2048 is being developed in collaboration with Braeburn Pharmaceuticals and has been successfully evaluated in a completed Phase I trial. The drug is currently being evaluated in Phase I/II stage of development.

ST 2427: SiteOne Therapeutics

ST-2427 is an experimental intravenous, non-opioid analgesic for the management of moderate-to-serve severe pain. ST-2427 blocks sodium ion channel 1.7 (NaV1.7). NaV1.7 is a type of sodium channel that is highly expressed in peripheral nerve fibers that play a critical role in the generation and conduction of pain signals.

As ST-2427 does not enter the brain, it is not expected to cause the central nervous system adverse effects (e.g. sedation, nausea, dependence and addition) that plague existing pain therapeutics such as the opioids. The development of ST-2427 was supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) under Award Number UG3DA049599.

Key Questions

• How many companies are developing Postoperative Pain drugs?
• How many Postoperative Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postoperative Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postoperative Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postoperative Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vivozon
• Grunenthal
• Apsen Farmaceutica
• Trevena
• Shijiazhuang Yiling Pharmaceutical
• Haisco Pharmaceutical Group
• Concentric Analgesics
• Salvat
• Unither Pharmaceuticals
• Formosa Pharmaceuticals
• Taiwan Liposome Company
• Novartis
• PainReform
• Oculis Pharma
• Mylan
• McNeil Consumer Pharmaceuticals
• Jiangsu Hengrui Medicine
• Jiangsu Hengrui Medicine
• Adynxx
• Teikoku Pharma USA
• Cali Pharmaceuticals
• ACADIA Pharmaceuticals
• Nevakar
• Cytogel
• Xgene Pharmaceutical
• Arthritis Innovation Corporation
• Mati Therapeutics
• SiteOne Therapeutics
• NeurOp
• Nang Kuang Pharmaceutical
• Flexion Therapeutics
• Hefei Cosource Pharmaceutical
• Layerbio

Key Products

• VVZ-149
• Qutenza
• APSCTC
• TRV130
• Felbinac trometamol
• HSK21542
• CA-008
• SVT-15473
• Nefopam hydrochloride
• APP13007
• TLC590
• SAF312
• PRF110
• OCS-01
• MR-107A-01
• JNJ-10450232
• HR18042
• HR021618
• AYX1
• Dexmedetomidine Transdermal System (DMTS)
• CPL- 01
• ACP-044
• NVK-009
• CYT 1010
• XG005
• F14
• Nepafenac PPDS/Nepafenac Evolute
• ST 2427
• NP 10679
• ND-340
• FX301
• HYR-PB21
• OcuRing-K

Key Topics Covered:

Introduction

Executive Summary

Postoperative Pain: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
• Postoperative Pain – The Publisher’s Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

VVZ-149: Vivozon

• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report

Mid Stage Products (Phase II)

• Comparative Analysis

TLC590: Taiwan Liposome Company

• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report

Early Stage Products (Phase I)

• Comparative Analysis

ST 2427: SiteOne Therapeutics

• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report

Preclinical and Discovery Stage Products

• Comparative Analysis

INSB200: InSitu Biologics

• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report

Inactive Products

• Comparative Analysis
• Postoperative Pain Key Companies
• Postoperative Pain Key Products
• Postoperative Pain- Unmet Needs
• Postoperative Pain- Market Drivers and Barriers
• Postoperative Pain- Future Perspectives and Conclusion
• Postoperative Pain Analyst Views
• Postoperative Pain Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lgu4qs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900